Fletcher Biosciences

Executive Summary

Fletcher Biosciences is a San Diego-based biotechnology company founded in 2019 that leverages a proprietary protein design platform to engineer natural immune proteins into precision immunotherapies. The company's core focus is on eliminating autoreactive T cells to restore immune balance, addressing complex autoimmune diseases with high unmet medical need. By engineering programmable biologics, Fletcher aims to provide targeted treatments that avoid the broad immunosuppression associated with conventional therapies. The company is currently in the preclinical stage and has not disclosed specific financials or pipeline details, but its platform technology represents a novel approach in the biologics space. Fletcher's strategy centers on its protein design platform, which enables the creation of highly specific immune-modulating molecules. The company is initially targeting autoimmune indications where autoreactive T cells play a pathogenic role. With a founding team likely experienced in protein engineering and immunology, Fletcher is positioned to advance its lead program toward IND-enabling studies. The biotech sector's growing interest in precision immunology and targeted protein therapeutics provides a favorable backdrop. Near-term success hinges on preclinical validation, securing financing, and establishing partnerships to support clinical development. Fletcher's differentiated platform and focus on high-value autoimmune targets warrant attention from investors seeking early-stage opportunities in the biologics space.

Upcoming Catalysts (preview)

• H2 2026Preclinical Data Presentation at Major Immunology Conference75% success
• Q3 2026Series A Financing Announcement60% success
• 2027Lead Program IND Filing40% success